5 Insightful Analyst Questions From Neogen's Q4 Earnings Call

Neogen’s Q4 results were met with a strong positive market reaction, reflecting the company’s return to positive core growth and substantial margin improvement. Management attributed the quarter’s performance to operational changes, including a sharper focus on cost structure and commercial execution. CEO Mike Nassif emphasized the shift to a process-oriented approach in the commercial organization, stating, “We are implementing a rigorous process-oriented approach to commercial excellence.” The addition of new leadership and targeted product focus, especially in food safety and sample collection, also contributed to the sequential margin expansion.

Is now the time to buy NEOG? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Neogen’s Q4 Earnings Call

• Bob Lovick (CJS Securities) asked about the onboarding and immediate impact of new executives. CEO Mike Nassif responded that “the caliber and experience of these professionals” allowed for rapid integration and focus on fundamentals.
• Lovick (CJS Securities) inquired about sample collection’s margin headwinds. CFO Brian Rigsby detailed sequential improvements and projected a return to profitability for the product line in the second half of the year.
• David Westenberg (Piper Sandler) questioned whether the outlook was conservative due to new leadership or macro factors. Nassif emphasized a prudent, credibility-focused approach in guidance, while Rigsby echoed that the team is settling in and prioritizing consistency.
• Westenberg (Piper Sandler) asked about one-time revenue tailwinds. Rigsby cited a $2 million insecticide benefit in animal safety but highlighted overall growth as primarily organic, not driven by unusual items.
• Brandon Vazquez (William Blair) explored the reasons for improved forecasting and commercial results. Nassif attributed success to weekly, cross-functional forecasting and a cultural shift toward supporting the sales team.

Catalysts in Upcoming Quarters

In the coming quarters, our analysts will watch for (1) further progress in operational efficiency, particularly in sample collection and inventory management, (2) successful integration and impact of new commercial leadership on sales execution and customer retention, and (3) the completion and effects of the genomics business divestiture. Monitoring end-market demand trends and the pace of recovery in food and animal safety segments will also be essential for assessing Neogen’s ongoing transformation.

Neogen currently trades at $9.41, up from $7.38 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).

The Best Stocks for High-Quality Investors

The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.